Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
BioCryst scraps eye drug to focus on rare diseases
BioCryst announced it has ended development of avoralstat, which was being studied to treat diabetic macular edema.
Will Maddox
May 6, 2026 10:40am
Ollin eyes phase 3 after topping Vabysmo in early-stage trial
Jan 8, 2026 3:20pm
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
Oct 31, 2025 5:09am
4DMT climbs as gene therapy patients keep jettisoning jabs
Aug 1, 2025 5:35am
Unity's stock tumbles after eye treatment fails to match Eylea
Mar 24, 2025 11:11am
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Jan 7, 2025 9:38am
